CKD: Semiconductor Demand Drives Earnings Upward Revision; Maintain Equal-weight

Overview

Morgan Stanley issued an earnings review for CKD (6407.T), raising earnings forecasts for FY F3/27 and F3/28, and increasing the target price from JPY 5,300 to JPY 5,700. The core logic is that expansion in semiconductor-related capital expenditure is driving a strong recovery in the Equipment Business, coupled with better-than-expected results in F3/26 Q4. Despite significant fundamental improvements, the report maintains an Equal-weight rating, considering that the stock price has risen sharply and already reflects earnings growth expectations for the next two years.

Core views

Earnings Forecast Revisions and Drivers: The report raised CKD's F3/27 operating profit forecast from JPY 25.5 billion to JPY 28.0 billion, and F3/28 from JPY 27.5 billion to JPY 30.0 billion. This adjustment is primarily based on stronger-than-expected F3/26 Q4 results and continued expansion in semiconductor-related demand. By segment, the Equipment Business is the core growth engine; operating profit for this segment is expected to grow 44% YoY to JPY 28.5 billion in F3/27, driven by surging semiconductor demand and gradual recovery in other end markets such as automobiles and machine tools. The Automation Machinery business is expected to remain largely flat YoY. Short-Term Performance Outlook: For F3/27 Q1, the report forecasts operating profit of JPY 7.0 billion, up 86% YoY and down 2% QoQ. The sequential decline is mainly due to seasonal factors in the Automation Machinery business, while the core Equipment Business is expected to achieve sequential profit growth driven by volume effects and improved capacity utilization. Management confirmed in post-earnings interviews that equipment demand has continued to expand from F3/26 Q4 into Q1 with no signs of slowing, but also noted potential upward pressure on costs as certain expenses become more visible. Valuation and Rating Logic: Despite improved earnings prospects, the report maintains an Equal-weight rating. The rationale is that the current stock price has already surged, and market expectations for substantial earnings improvement over the next two years are largely priced in. The new target price of JPY 5,700 is derived by applying a 2.1x P/B multiple to the estimated F3/28 Book Value Per Share (BPS) of JPY 2,734; the target multiple remains unchanged. This valuation implies a premium relative to historical levels, reflecting structural improvements in profitability and a general re-rating of TOPIX valuations.

Analysis framework

The report employs a 'bottom-up fundamentals + relative valuation anchoring' analytical framework. It first assesses revenue elasticity across business segments by tracking semiconductor capex cycles and end-market demand (e.g., automobiles, machine tools), thereby deriving profit growth rates resulting from operating leverage. On the valuation front, rather than relying solely on P/E, the firm uses P/B as the core anchor, as net asset value provides a better reference for margin of safety in asset-heavy or cyclical manufacturing industries. Analysts constructed an 'ROE-P/B regression model' to determine a fair P/B multiple, and applied additional premiums to the base fair value based on three factors: the company's earnings growth trajectory (exceeding historical peaks), historical premium conventions during industry upcycles, and an upward shift in broader market valuation benchmarks, ultimately arriving at the final target price.

Methodology notes

• Valuation MethodologyPB valuation

  ROE-P/B Regression Pricing Model

  The report establishes a historical regression equation correlating ROE and P/B to calculate the theoretical fair P/B for a given ROE level (e.g., ROE of 12.7% corresponds to P/B of 1.0x). Additional premiums are then applied based on qualitative factors such as earnings growth rate, cycle positioning, and broader market conditions. This approach avoids arbitrary multiple assignment, providing statistical support while allowing flexibility to reflect fundamental changes.

• Industry Analysis FrameworkSupply Chain Transmission Mechanism

  Semiconductor Capex Transmission Mechanism

  As an upstream component/equipment supplier, CKD's performance is highly dependent on downstream semiconductor manufacturers' capital expenditure (Capex). The report treats 'semiconductor Capex expansion' as a core variable, directly mapping it to order and profit growth in the company's Equipment Business. Understanding this transmission chain is key to assessing sentiment for such companies; monitoring downstream wafer fab expansion plans offers more forward-looking insight than focusing solely on the company itself.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• CKD (6407.T)

  Direct beneficiary of semiconductor Capex expansion; Equipment Business serves as core growth driver

  Strengths

  Strong recovery in semiconductor-related demand; profit margins expected to rebound to historical peaks; F3/27-28 earnings forecasts revised upward

  Weaknesses

  Stagnant growth in Automation Machinery business; stock price has risen significantly reflecting expectations; facing upward cost pressures

  Risks

  Slowdown in chip Capex; Japan/China manufacturing investment falling short of expectations; increases in component and fixed costs

Key data

• F3/27 Operating Profit ForecastJPY 28.0 bnRevised up by JPY 2.5 bn from previous forecast, primarily driven by semiconductor equipment demand
• F3/28 Operating Profit ForecastJPY 30.0 bn+7% YoY; operating margin expected to improve to 15.4%
• F3/27 Q1 Operating Profit ForecastJPY 7.0 bn+86% YoY, -2% QoQ (seasonal factors)
• New Target PriceJPY 5,700Based on F3/28 BPS of JPY 2,734 × 2.1x P/B; raised from previous target of JPY 5,300
• Equipment Business F3/27 OP Growth+44% YoYStrong recovery in semiconductor demand combined with gradual recovery in other end markets

Impact & implications

The report suggests CKD is on a path to earnings recovery driven by the semiconductor cycle, with profit margins poised to return to historical peak levels. For investors, this indicates increased certainty in the company's fundamentals, but the current stock price has already digested this positive news. Future alpha generation may no longer come simply from 'recovery realization,' but will require observation of whether semiconductor Capex expands beyond expectations, whether new customer development proceeds smoothly, or whether general manufacturing investment picks up the baton. If the current pace of recovery merely continues, the stock price is likely to exhibit range-bound oscillation in line with earnings growth rather than further multiple expansion.

Risks

• Chip industry Capex recovery falling short of expectations or slowing again
• Weak recovery in general manufacturing Capex in Japan and China
• Rising costs for components, raw materials, and fixed expenses eroding profit margins

What to watch

• Sales growth of pneumatic equipment and semiconductor fluid control equipment in Japanese and overseas markets
• Progress in profitability improvements achieved through automation and productivity enhancements
• Development and cultivation progress of new U.S. customers
• Acquisition of new customers in the semiconductor industry